Altered nerve excitability in subclinical/early diabetic neuropathy: Evidence for early neurovascular process in diabetes mellitus?

Diabetes Research and Clinical Practice

Volumn 91, Issue 2, 2011, Pages 183-189

  Bae, Jong Seok ^a   Kim, Oeung Kyu ^a   Kim, Jae Moon ^b  

^a Inje University College of Medicine   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Axonal excitability; Diabetic neuropathy; Nerve excitability testing; Neurovascular; Subclinical

Indexed keywords

HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PH; CLINICAL ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DIABETIC NEUROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; ION CONDUCTANCE; ISCHEMIA; MALE; MICROANGIOPATHY; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION; NERVE EXCITABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REFRACTORY PERIOD; STIMULUS RESPONSE;

ADULT; DIABETES MELLITUS; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL NERVES;

EID: 79952041354     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.11.008     Document Type: Article

References (41)

1. Argoff C.E., Cole B.E., Fishbain D.A., Irving G.A. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006, 81:S3-S11.
2. Dobretsov M., Romanovsky D., Stimers J.R. Early diabetic neuropathy: triggers and mechanisms. World J Gastroenterol 2007, 13:175-191.
3. Vinik A.I., Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004, 88:947-999. xi.
4. Pastore C., Izura V., Geijo-Barrientos E., Dominguez J.R. A comparison of electrophysiological tests for the early diagnosis of diabetic neuropathy. Muscle Nerve 1999, 22:1667-1673.
5. Olaleye D., Perkins B.A., Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001, 54:115-128.
6. Rith-Najarian S.J., Stolusky T., Gohdes D.M. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria. Diabetes Care 1992, 15:1386-1389.
7. Dyck P.J., Kratz K.M., Lehman K.A., Karnes J.L., Melton L.J., O'Brien P.C., et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991, 41:799-807.
8. DCCT The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
9. Lasker R.D. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med 1993, 329:1035-1036.
10. Gordon Smith A., Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci 2006, 242:9-14.
11. Dyck P.J., Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 1996, 55:1181-1193.
12. Sima A.A. Metabolic alterations of peripheral nerve in diabetes. Semin Neurol 1996, 16:129-137.
13. Kuwabara S., Misawa S. Axonal ionic pathophysiology in human peripheral neuropathy and motor neuron disease. Curr Neurovasc Res 2004, 1:373-379.
14. Misawa S., Kuwabara S., Kanai K., Tamura N., Hiraga A., Nakata M., et al. Axonal potassium conductance and glycemic control in human diabetic nerves. Clin Neurophysiol 2005, 116:1181-1187.
15. Misawa S., Kuwabara S., Ogawara K., Kitano Y., Hattori T. Strength-duration properties and glycemic control in human diabetic motor nerves. Clin Neurophysiol 2005, 116:254-258.
16. Misawa S., Kuwabara S., Ogawara K., Kitano Y., Yagui K., Hattori T. Hyperglycemia alters refractory periods in human diabetic neuropathy. Clin Neurophysiol 2004, 115:2525-2529.
17. Yerdelen D., Koc F., Uysal H., Sarica Y. Strength-duration properties in diabetic polyneuropathy. Diabetes Res Clin Pract 2007, 78:56-59.
18. Horn S., Quasthoff S., Grafe P., Bostock H., Renner R., Schrank B. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve 1996, 19:1268-1275.
19. Dyck P.J. Severity and staging of diabetic polyneuropathy. Textbook of diabetic neuropathy 2003, 170-175. Georg Thieme Verlag, New York. F. Arnold Gries, N.E. Cameron, P.A. Low, D. Ziegler (Eds.).
20. Froissart M., Rossert J., Jacquot C., Paillard M., Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005, 16:763-773.
21. Mogyoros I., Kiernan M.C., Burke D. Strength-duration properties of human peripheral nerve. Brain 1996, 119(Pt 2):439-447.
22. Z'Graggen W.J., Lin C.S., Howard R.S., Beale R.J., Bostock H. Nerve excitability changes in critical illness polyneuropathy. Brain 2006, 129:2461-2470.
23. Greene D.A., Lattimer S.A., Sima A.A. Pathogenesis and prevention of diabetic neuropathy. Diabetes Metab Rev 1988, 4:201-221.
24. Ambrosch A., Dierkes J., Lobmann R., Kuhne W., Konig W., Luley C., et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet Med 2001, 18:185-192.
25. Rabinowe S.L. Immunology of diabetic and polyglandular neuropathy. Diabetes Metab Rev 1990, 6:169-188.
26. Cameron N.E., Cotter M.A. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994, 10:189-224.
27. Dyck P.J., Hansen S., Karnes J., O'Brien P., Yasuda H., Windebank A., et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 1985, 82:2513-2517.
28. Low P.A. Recent advances in the pathogenesis of diabetic neuropathy. Muscle Nerve 1987, 10:121-128.
29. Nodera H., Kaji R. Nerve excitability testing and its clinical application to neuromuscular diseases. Clin Neurophysiol 2006, 117:1902-1916.
30. Devor M., Wall P.D., Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992, 48:261-268.
31. Bos M.J., Koudstaal P.J., Hofman A., Breteler M.M. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007, 38:3127-3132.
32. Ovbiagele B. Impairment in glomerular filtration rate or glomerular filtration barrier and occurrence of stroke. Arch Neurol 2008, 65:934-938.
33. Ito H., Takeuchi Y., Ishida H., Antoku S., Abe M., Mifune M., et al. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 2009, 25:1161-1167.
34. Krishnan A.V., Kiernan M.C. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005, 128:1178-1187.
35. Russell J.W., Feldman E.L. Impaired glucose tolerance-does it cause neuropathy?. Muscle Nerve 2001, 24:1109-1112.
36. Singleton J.R., Smith A.G., Bromberg M.B. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001, 24:1225-1228.
37. Singleton J.R., Smith A.G., Russell J., Feldman E.L. Polyneuropathy with impaired glucose tolerance: implications for diagnosis and therapy. Curr Treat Options Neurol 2005, 7:33-42.
38. Kempler P., Tesfaye S., Chaturvedi N., Stevens L.K., Webb D.J., Eaton S., et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002, 19:900-909.
39. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., Ionescu-Tirgoviste C., et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
40. Steinmetz A. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. Diabetes Metab Res Rev 2008, 24:286-293.
41. Wiggin T.D., Sullivan K.A., Pop-Busui R., Amato A., Sima A.A., Feldman E.L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634-1640.